Products
HuPrime®
Immuno-Oncology
February 18, 2020
Using Liver-Targeted Mitochondrial Uncoupling to Resolve Fatty Liver Disease
Explore how liver-targeted mitochondrial uncoupling is resolving fatty liver disease in preclinical models, with the potential for future clinical use.
WEBINAR: 3D In Vitro Drug Discovery
When and How to Use Tumor Organoids
Thursday February 27 - 3am/10am/5pm ET
Join Dr Rajendra Kumari to explore the best time to implement tumor organoids in your drug development programs. Review the key differences between 3D in vitro systems, including organoids and primary cells, and how to select the right 3D in vitro platform based on model features, benefits, and limitations.
ON DEMAND WEBINAR: 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical Space
Join Mike Batey to learn how to apply systems biology in early stage drug development for biomarker discovery and validation. Review 3 case studies exploring novel strategies to identify and utilize biomarkers using translational preclinical models, including using in vitro models to uncover genetic signatures of response and in vivo PDX to dissect drug MoA and guide clinical trial design.
NEW WHITE PAPER: Applications of HUB Tumor Organoids in Oncology Drug Development
Learn more about PDX-derived tumor organoids (PDXO) developed using HUB protocols, as robust in vitro models to improve the predictivity and speed of preclinical drug discovery. Review the main applications of 3D PDXO including large-scale drug screening, in vivo model selection, and in silico drug discovery.
ON DEMAND WEBINAR: Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)
Presented by Dr Leigh Goedeke, Yale School of Medicine this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.
NEW WHITE PAPER: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies
Learn how to optimize preclinical model selection for CAR-T cell therapy assessment through understanding available model advantages and limitations, alongside your study aims. Explore a multiparameter imaging and analysis platform for improved CAR-T cell detection and characterization to enhance clinical development and success.
ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids
Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.
NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs
Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.
NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling
Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.
WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model
Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.
